An alarming trend is emerging around GLP-1 medications like Ozempic, which are often hailed for their weight-loss benefits. Are we about to see these drugs face severe scrutiny? This week, leading dietitians in Australia have raised significant concerns regarding an overlooked consequence of this class of weight-loss medications, which includes Ozempic, Wegovy, and Mounjaro.
A recent systematic review spearheaded by Professor Clare Collins from the Newcastle School of Health Sciences in New South Wales has revealed that a strikingly small number of global clinical trials examining these drugs have focused on the dietary habits and nutritional intake of patients using them. This glaring oversight suggests that many individuals may be experiencing functional malnutrition, leading to dangerous vitamin shortages such as scurvy—a condition typically associated with sailors of centuries past.
The efficacy of these medications in managing weight and diabetes largely stems from their ability to suppress appetite. However, the lack of adequate nutrition—whether due to reduced food intake or poor dietary choices—is not a viable long-term solution for anyone, regardless of their use of GLP-1 drugs, prompting dietitians to call for enhanced regulatory measures.
"Just because someone loses weight doesn’t mean they are nutritionally healthy or well," Collins emphasized in her comments to the Australian Financial Review. "Nutrition is fundamental to overall health, yet it seems to be largely absent from the current research evidence."
One notable instance of scurvy surfaced last year when British singer Robbie Williams described his diagnosis as a "17th century pirate disease." He had been vocal about his use of injectable weight-loss treatments and has linked his deteriorating eyesight to their effects.
Historically, scurvy—a deficiency of vitamin C—was a common peril for sailors, but it has become quite rare in contemporary societies such as the US, UK, and Australia, where people generally maintain nutrient-rich diets. However, Collins has reported that several physicians have recently noted cases of scurvy among their patients. "We shouldn’t wait for every general practitioner to encounter a case of scurvy before we take action; let’s proactively connect these long-term management plans with dietitian referrals," she stated.
Moreover, reports indicate that the use of GLP-1 medications has also been tied, albeit infrequently, to thiamine deficiency, which can lead to serious neurological and cardiovascular issues.
Collins's investigation analyzed over 40 studies conducted over 17 years, involving more than 50,000 participants, yet only two of these studies considered the dietary patterns of the patients. This lack of data is troubling. "Out of all the trials, only one disclosed dietary habits, and we reached out to the authors of each study, receiving data from just one additional source. This critical aspect is being overlooked," she explained. "This gap means we fail to understand how these drugs might influence dietary intake. Given the known side effects, this is a significant oversight considering the cost involved."
In addition to common side effects like nausea and dizziness, other serious complications related to GLP-1 usage are becoming increasingly recognized, ranging from the development of eating disorders to rare forms of cancer.
However, don’t cast all weight-loss medications aside just yet. Ozempic and Wegovy, both branded versions of semaglutide, offer notable advantages for certain individuals, and ongoing research continues to uncover effective uses for these drugs. Some experts in longevity even suggest that microdoses of semaglutide could serve as an anti-aging treatment, potentially lowering the risk of heart attacks, strokes, and metabolic diseases.
In 2024, a National Institute of Health survey found that 12% of American adults had utilized a GLP-1 medication, with the percentage exceeding 25% among adults diagnosed with diabetes, according to the CDC. With figures like these, it’s evident that these medications are here to stay. Yet, without robust dietary guidance, many patients may feel abandoned by their healthcare providers.
Magriet Raxworthy, the CEO of Dietitians Australia, stressed the necessity of personalized nutritional therapy from dietitians for those on GLP-1 treatments to avert further instances of scurvy and related complications. "Without proper support, individuals may find it difficult to meet their nutritional requirements, risking significant muscle and bone density loss as well as micronutrient deficiencies and disordered eating patterns," she cautioned.
"It’s clear that relying solely on medication is insufficient to achieve sustainable health outcomes."
What are your thoughts on the implications of GLP-1 medications? Do you agree that nutritional guidance is essential, or do you believe the focus should remain solely on medication for weight loss? Share your views in the comments!
